Rocket Pharmaceuticals, Inc. Warrant
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; l… Read more
Rocket Pharmaceuticals, Inc. Warrant (RCKTW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: -0.158x
Based on the latest financial reports, Rocket Pharmaceuticals, Inc. Warrant (RCKTW) has a cash flow conversion efficiency ratio of -0.158x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.10 Million) by net assets ($329.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rocket Pharmaceuticals, Inc. Warrant - Cash Flow Conversion Efficiency Trend (2019–2023)
This chart illustrates how Rocket Pharmaceuticals, Inc. Warrant's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Rocket Pharmaceuticals, Inc. Warrant Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rocket Pharmaceuticals, Inc. Warrant ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OLYMPIA CAPITAL CORPORATION (BOTSWANA) LIMITED
XBOT:OCCL-EQO
|
N/A |
|
Boba Mint Holdings Ltd
F:84L
|
N/A |
|
GLG LIFE TECH (9LTN.SG)
STU:9LTN
|
0.002x |
|
TLT
WAR:TLT
|
N/A |
|
MEGASTAR DEV
BE:M5QN
|
-0.239x |
|
Nedbank Group Limited Zimbabwe Depository Receipts
VFEX:NULL
|
N/A |
|
FIRST SHANGHAI INV
BE:FSI
|
N/A |
|
Haus Talk Inc
PSE:HTI
|
-0.045x |
Annual Cash Flow Conversion Efficiency for Rocket Pharmaceuticals, Inc. Warrant (2019–2023)
The table below shows the annual cash flow conversion efficiency of Rocket Pharmaceuticals, Inc. Warrant from 2019 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $492.57 Million | $-194.92 Million | -0.396x | -8.77% |
| 2022-12-31 | $489.69 Million | $-178.14 Million | -0.364x | -36.53% |
| 2021-12-31 | $454.72 Million | $-121.16 Million | -0.266x | -79.75% |
| 2020-12-31 | $503.52 Million | $-74.64 Million | -0.148x | +29.55% |
| 2019-12-31 | $307.30 Million | $-64.66 Million | -0.210x | -- |